Epidemiology of coronary heart disease in patients with human immunodeficiency virus

Reviews in Cardiovascular Medicine

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Triant, Virginia A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral therapy; Cardiovascular disease; Coronary heart disease; Human immunodeficiency virus; Inflammation; Risk factors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; VIRUS RNA;

AGE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CHRONIC INFLAMMATION; CORONARY RISK; DIABETES MELLITUS; DRUG EXPOSURE; DYSLIPIDEMIA; FEMININITY; GLUCOSE INTOLERANCE; HEALTH CARE DELIVERY; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MIXED INFECTION; OBESITY; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; VIRUS LOAD;

ANTI-HIV AGENTS; CHRONIC DISEASE; CORONARY DISEASE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; INFLAMMATION; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 84903792651     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3908/ricm15S1S002     Document Type: Review

References (36)

1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448-457.
2. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387-1396.
3. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61:511-523.
4. Grinspoon S, Carr A. Cardiovascular risk and bodyfat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
5. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
6. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512. (Pubitemid 36886080)
7. Mary-Krause M, Cotte L, Simon A, et al Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486. (Pubitemid 38393320)
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512. (Pubitemid 47037350)
9. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-1631. (Pubitemid 46871511)
10. Lang S, Mary-Krause M, Cotte L, et al; French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-1230.
11. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57:245-253.
12. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
13. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
14. Silverberg M, Leyden W, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160-166.
15. Petrosillo N, Cicalini S. Smoking and HIV: time for a change? BMC Med. 2013;11:16.
16. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710. (Pubitemid 36237039)
17. Friis-Møller N, Reiss P, Sabin CA, et al DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735. (Pubitemid 46658704)
18. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-330.
19. Lang S, Mary-Krause M, Cotte L, et al Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency vi-rus- infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-1238.
20. Monforte Ad, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS. 2013;27:407-415.
21. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PloS One. 2013;8:e59551.
22. Lichtenstein KA, Armon C, Buchacz K, et al HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-447.
23. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55:615-619.
24. Lang S, Mary-Krause M, Simon A, et al; French Hospital Database on HIV (FHDH)-ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIVinfected individuals. Clin Infect Dis. 2012;55:600-607.
25. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non- HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351-358.
26. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr. 2009;51:399-406.
27. Julius H, Basu D, Ricci E, et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Curr HIV Res. 2011;9:247-252.
28. Wester CW, Koethe JR, Shepherd BE, et al. Non- AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS. 2011;25:1471-1479.
29. Bedimo R, Westfall AO, Mugavero M, et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468.
30. Freiberg MS, Chang CC, Skanderson M, et al Veterans Aging Cohort Study. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4:425-432.
31. Weber R, Sabin C, Reiss P, et al Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15:1077-1086.
32. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25:1637-1646.
33. Ye Y, Zeng Y, Li X, et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr. 2010;53:276-278.
34. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737-743.
35. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891-1896.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Web site. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed February 11, 2014.